PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Summary

Background

PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) in French and Burkinabe women who were not pregnant.

Methods

This first-in-human, randomised, double-blind, placebo-controlled, dose escalation trial was done in two staggered phases, a phase 1A trial in 18–35-year-old women who were malaria naive in a hospital in France and a subsequent phase 1B trial in women who were naturally exposed to P falciparum and nulligravid in the clinical site of a research centre in Burkina Faso. Volunteers were recruited into four sequential cohorts receiving PRIMVAC intramuscularly at day 0, 28, and 56: two cohorts in France receiving 20 μg or 50 μg of PRIMVAC and then two in Burkina Faso receiving 50 μg or 100 μg of PRIMVAC. Volunteers were randomly assigned (1:1) to two groups (PRIMVAC adjuvanted with either Alhydrogel or GLA-SE) in France and randomly assigned (2:2:1) to three groups (PRIMVAC adjuvanted with either Alhydrogel, GLA-SE, or placebo) in Burkina Faso. Randomisation was centralised, using stratification by cohort and blocks of variable size, and syringes were masked by opaque labels. The primary endpoint was the proportion of participants with any grade 3 or higher adverse reaction to vaccination up until day 35. Safety at later time points as well as humoral and cellular immunogenicity were assessed in secondary endpoints. This trial is registered with ClinicalTrials.gov, NCT02658253.

Findings

Between April 19, 2016, and July 13, 2017, 68 women (18 in France, 50 in Burkina Faso) of 101 assessed for eligibility were included. No serious adverse event related to the vaccine occurred. PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57). PRIMVAC antibody titres reached a peak (geometric mean 11 843·0, optical density [OD] 1·0, 95% CI 7559·8–18 552·9 with 100 μg dose and GLA-SE) 1 week after the third vaccination (day 63). Compared with Alhydrogel, GLA-SE tended to improve the PRIMVAC antibody response (geometric mean 2163·5, OD 1·0, 95% CI 1315·7–3557·7 with 100 μg dose and Alhydrogel at day 63). 1 year after the last vaccination, 20 (71%) of 28 women who were vaccinated with PRIMVAC/Alhydrogel and 26 (93%) of 28 women who were vaccinated with PRIMVAC/GLA-SE still had anti-PRIMVAC antibodies, although antibody magnitude was markedly lower (452·4, OD 1·0, 95% CI 321·8–636·1 with 100 μg dose and GLA-SE). These antibodies reacted with native homologous VAR2CSA expressed by NF54-CSA infected erythrocytes (fold change from baseline at day 63 with 100 μg dose and GLA-SE: 10·74, 95% CI 8·36–13·79). Limited cross-recognition, restricted to sera collected from women that received the 100 μg PRIMVAC dose, was observed against heterologous VAR2CSA variants expressed by FCR3-CSA (fold change from baseline at day 63: 1·49, 95% CI 1·19–1·88) and 7G8-CSA infected erythrocytes (1·2, 1·08–1·34).

Interpretation

PRIMVAC adjuvanted with Alhydrogel or GLA-SE had an acceptable safety profile, was immunogenic, and induced functional antibodies reacting with the homologous VAR2CSA variant expressed by NF54-CSA infected erythrocytes. Cross-reactivity against heterologous VAR2CSA variants was limited and only observed in the higher dose group. An alternate schedule of immunisation, antigen dose, and combinations with other VAR2CSA-based vaccines are envisaged to improve the cross-reactivity against heterologous VAR2CSA variants.

Funding

Bundesministerium für Bildung und Forschung, through Kreditanstalt für Wiederaufbau, Germany; Inserm, and Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland.

Introduction

According to the 2019 WHO malaria report, 228 million cases of malaria occurred in 2018 leading to 405 000 deaths.¹ The majority of clinical cases and deaths occurred in sub-Saharan Africa and mainly resulted from Plasmodium falciparum infection. In malaria endemic areas, individuals progressively acquire clinical immunity during childhood and adults are therefore generally protected against the severe clinical outcomes of the disease.² However, during their first pregnancies, women become once again susceptible to the serious clinical outcomes associated with placental malaria.³ Placental malaria can lead to maternal anaemia, hypertension, and stillbirth. Their infant can have low birthweight due to premature delivery and fetal growth retardation.³ Low birthweight is an important risk factor for neonatal and infant death.⁴ A modelling study showed that up to 40% of pregnant women in sub-Saharan Africa develop placental malaria.⁵ Furthermore, P falciparum malaria was responsible for 11% of low birthweight-related infant mortality in sub-Saharan Africa⁶ and an estimate of 217 026 stillbirths (20% of all stillbirths in sub-Saharan Africa).⁷ Remarkably, the prevalence of placental malaria sharply drops with successive pregnancies.⁴ This protection has been associated with the development of antibodies directed towards the surface of infected erythrocytes from placental origin.⁸ Therefore, a vaccine priming the immunity observed in women who are multigravid could have a large effect on both disease incidence and severity and possibly save around 100 000 lives each year.³

The severe outcomes of placental malaria results from the massive accumulation of infected erythrocytes in the placental intervillous spaces² through the binding to the placental chondroitin sulfate A (CSA), a binding phenotype not seen outside of the pregnancy context.⁹ Infected erythrocyte adhesion is mediated by the highly diverse P falciparum erythrocyte membrane protein 1 family (PfEMP1) encoded by the var genes.²

Evidence strongly supports the PfEMP1-VAR2CSA variant as the leading candidate for a placental malaria vaccine. Indeed, VAR2CSA is preferentially expressed by infected erythrocytes from placental origin¹⁰ and recombinant VAR2CSA binds to CSA.¹¹ Genetic deletion of var2csa results in the loss of infected erythrocyte adhesion to CSA that cannot be compensated by any other PfEMP1.¹² Antisera to recombinant VAR2CSA react to the surface of CSA-binding infected erythrocytes and inhibit their adhesion to CSA.13, 14, 15 Women gradually acquire strain-transcendent antibodies recognising recombinant and native VAR2CSA expressed on infected erythrocytes, which also inhibit infected erythrocyte adhesion to the placenta, thus correlating with placental malaria protection.8, 16, 17 Taken together, these data provide a rational basis for developing a VAR2CSA-derived placental malaria vaccine. Two placental malaria vaccine candidates (PRIMVAC and PAMVAC) are currently under clinical development.¹⁸ Following an extensive screening study, PRIMVAC spanning the CSA-binding DBL1x-2x region of the 3D7-VAR2CSA variant was selected¹⁵ and transitioned to current good manufacturing practice production.¹⁹ Preliminary safety and immunogenicity results of the PAMVAC study, assessing a placental malaria vaccine derived from the FCR3-VAR2CSA variant in volunteers who were malaria naive in Germany, reported that PAMVAC is safe and can induce functional antibodies against the homologous VAR2CSA-expressing strain.²⁰

We aimed to assess the safety and immunogenicity of PRIMVAC in both women who were malaria naive and not pregnant in France and in women who were P falciparum-naturally exposed and nulligravid in Burkina Faso.